Jardiance vs Ocrevus
Side-by-side drug price comparison from Medicare Part D data
Verdict
Jardiance costs 99% less per claim than Ocrevus ($210.00 vs $23635.00). Jardiance has a generic alternative available. Total Medicare spending: Jardiance at $3.9B vs Ocrevus at $3.5B.
| Metric | Jardiance | Ocrevus |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $210* | $23,635 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $3.9B | $3.5B |
| Total Claims | 18,760,000 | 148,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 22.7% | 16.5%* |
| Generic Available | Yes | Yes |
| Condition | Diabetes | Multiple Sclerosis |
| Total Beneficiaries | 2,150,000 | 62,000 |
Jardiance costs 99% less per claim than Ocrevus ($210.00 vs $23635.00). Jardiance has a generic alternative available. Total Medicare spending: Jardiance at $3.9B vs Ocrevus at $3.5B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Jardiance and Ocrevus. What follows is the interpretation — which specific axes carry the most weight for Jardiance versus Ocrevus, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.